Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Leukopenias NECCytochrome P450 1A2P05177Not Available11600468; 11856081; 11600469
VasculitisMyeloperoxidaseP05164T234717913504; 7913503; 8102951; 7914458; 8624621; 7869327; 7835022; 8095074; 8624617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flatulence07.01.04.002--
Folate deficiency14.12.02.006--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gamma-glutamyltransferase increased13.03.01.011--
Gastric ulcer07.04.03.0020.001382%
Gastrooesophageal reflux disease07.02.02.0030.002763%
Gastrointestinal disorder07.11.01.0010.021414%Not Available
Gastrointestinal pain07.01.05.005--
Glomerulonephritis20.05.01.001; 10.02.01.0060.002763%Not Available
Glomerulonephritis rapidly progressive20.05.01.004; 10.04.04.0080.001382%Not Available
Glossodynia07.14.02.0010.001382%Not Available
Glycosylated haemoglobin decreased13.02.02.0120.003454%Not Available
Goitre14.11.01.008; 05.02.01.001--Not Available
Granulocytopenia01.02.03.0030.002763%Not Available
Granuloma23.03.15.001; 08.01.05.0010.001382%Not Available
Guillain-Barre syndrome11.07.01.001; 10.04.10.005; 17.09.01.001--
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin decreased13.01.05.003--Not Available
Haemolysis01.06.04.0020.006217%
Haemolytic anaemia01.06.03.0020.001382%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.001--
Hallucination19.10.02.002--
Headache17.14.01.0010.028321%
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.002763%Not Available
Hepatic necrosis09.01.07.0020.000360%
Hepatic steatosis14.08.04.005; 09.01.07.0030.002763%Not Available
Hepatitis09.01.07.0040.003454%Not Available
Hepatitis acute09.01.07.0050.002763%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 15 Pages